Testamidė - Company finances
|
EUR
|
2021
From: 2021-11-04
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | - | 294,021 | 60,342 | 52,816 | 134,975 |
| Profit before tax | 0 | 633 | -43,787 | -28,832 | 16,001 |
| Net profit | 0 | 601 | -43,787 | -28,832 | 16,001 |
| Equity | 2,500 | 3,101 | -40,686 | -69,920 | -53,919 |
| Liabilities | 1,038 | 56,525 | 106,300 | 104,886 | 128,863 |
| Non-current assets | 0 | 20,502 | 15,972 | 10,428 | 5,898 |
| Current assets | 3,041 | 39,124 | 49,642 | 24,538 | 69,046 |
| Total assets | 3,041 | 59,626 | 65,614 | 34,966 | 74,944 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 11,786 | 3,109 | 5,560 |
| Social insurance contributions | - | - | 7,512 | 6,660 | 8,721 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | - | -79.5% | -12.5% | +155.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.0% | 1.0% | -66.7% | -82.5% | 21.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.0% | 19.4% | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 0.2% | -72.6% | -54.6% | 11.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 0.2% | -72.6% | -54.6% | 11.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 18.2 | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 21,514 | 6,408 | 4,660 | 10,383 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Testamidė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-03-27 | 2026-03-27 | 724.73 |
| 2026-03-17 | 2026-03-18 | 724.73 |
| 2025-04-18 | 2025-04-21 | 198.72 |
| 2025-04-17 | 2025-04-17 | 593.72 |
| 2025-04-01 | 2025-04-01 | 23.85 |
| 2025-03-28 | 2025-03-31 | 78.45 |
| 2025-03-27 | 2025-03-27 | 148.98 |
| 2025-03-19 | 2025-03-26 | 266.21 |
| 2025-02-19 | 2025-02-20 | 348.54 |
| 2025-01-22 | 2025-01-23 | 279.16 |
| 2025-01-20 | 2025-01-21 | 509.16 |
| 2025-01-17 | 2025-01-19 | 519.48 |
| 2024-12-30 | 2024-12-31 | 472.46 |
| 2024-12-27 | 2024-12-29 | 517.01 |
| 2024-11-21 | 2024-11-21 | 274.53 |
| 2024-11-19 | 2024-11-20 | 531.53 |
| 2024-11-04 | 2024-11-04 | 147.46 |
| 2024-10-30 | 2024-11-03 | 197.19 |
| 2024-10-29 | 2024-10-29 | 329.60 |
| 2024-10-25 | 2024-10-28 | 494.16 |
| 2024-10-16 | 2024-10-24 | 576.94 |
| 2024-09-23 | 2024-09-24 | 104.57 |
| 2024-09-19 | 2024-09-22 | 444.57 |
| 2024-09-17 | 2024-09-18 | 574.57 |
| 2024-08-29 | 2024-09-02 | 72.47 |
| 2024-08-28 | 2024-08-28 | 120.99 |
| 2024-08-22 | 2024-08-27 | 306.93 |
| 2024-08-19 | 2024-08-21 | 438.93 |
| 2024-08-05 | 2024-08-13 | 1.61 |
| 2024-07-31 | 2024-08-04 | 122.80 |
| 2024-07-25 | 2024-07-30 | 299.16 |
| 2024-07-24 | 2024-07-24 | 300.55 |
| 2024-07-16 | 2024-07-23 | 298.94 |
| 2024-06-18 | 2024-07-15 | 0.26 |
| 2024-05-22 | 2024-05-26 | 202.09 |
| 2024-05-17 | 2024-05-21 | 402.09 |
| 2024-05-16 | 2024-05-16 | 625.09 |
| 2024-04-23 | 2024-05-15 | 1.79 |
| 2024-04-18 | 2024-04-22 | 0.03 |
| 2024-04-17 | 2024-04-17 | 85.03 |
| 2024-04-16 | 2024-04-16 | 585.03 |
| 2024-02-27 | 2024-02-27 | 319.45 |
| 2024-02-20 | 2024-02-26 | 344.36 |
| 2024-02-19 | 2024-02-19 | 394.36 |
| 2023-12-27 | 2023-12-28 | 294.24 |
| 2023-12-20 | 2023-12-26 | 494.24 |
| 2023-12-18 | 2023-12-19 | 615.24 |
| 2023-11-16 | 2023-11-16 | 399.81 |
| 2023-08-18 | 2023-08-20 | 448.59 |
| 2023-08-17 | 2023-08-17 | 586.59 |
| 2023-07-21 | 2023-07-23 | 397.37 |
| 2023-07-18 | 2023-07-20 | 597.37 |
| 2023-06-19 | 2023-06-19 | 19.73 |
| 2023-06-16 | 2023-06-18 | 119.73 |
| 2023-01-24 | 2023-01-25 | 397.06 |
| 2023-01-20 | 2023-01-23 | 585.06 |
| 2023-01-17 | 2023-01-19 | 584.77 |
| 2022-10-28 | 2022-11-16 | 1.52 |
| 2022-08-23 | 2022-09-12 | 42.47 |
| 2022-07-29 | 2022-07-31 | 159.90 |
| 2022-07-18 | 2022-07-28 | 570.51 |
| 2022-06-28 | 2022-06-28 | 998.59 |
| 2022-06-27 | 2022-06-27 | 1318.71 |
| 2022-06-17 | 2022-06-26 | 1510.57 |
| 2022-06-16 | 2022-06-16 | 2510.57 |
| 2022-05-19 | 2022-06-15 | 0.14 |
| 2022-05-17 | 2022-05-18 | 263.14 |
| 2022-04-25 | 2022-05-15 | 1.25 |
| 2022-04-19 | 2022-04-20 | 206.56 |
| 2022-03-16 | 2022-03-24 | 251.07 |
Testamidė - VMI tax arrears
As of 2026-09-14, the amount of overdue STI tax debt of the company Testamidė is: 409 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-11 | 2026-09-14 | 409.11 |
| 2026-09-02 | 2026-09-10 | 1.67 |
| 2026-08-28 | 2026-09-01 | 22.16 |
| 2026-08-16 | 2026-08-27 | 103.55 |
| 2026-08-13 | 2026-08-15 | 483.55 |
| 2026-08-12 | 2026-08-12 | 480.55 |
| 2026-08-02 | 2026-08-11 | 1.89 |
| 2026-07-16 | 2026-08-01 | 0.17 |
| 2026-06-17 | 2026-07-15 | 1.73 |
| 2026-05-19 | 2026-06-05 | 1.37 |
| 2026-05-17 | 2026-05-18 | 0.32 |
| 2026-04-22 | 2026-04-30 | 3.76 |
| 2026-04-17 | 2026-04-21 | 3.6 |
| 2026-04-14 | 2026-04-16 | 603.04 |
| 2026-04-11 | 2026-04-13 | 764.35 |
| 2026-03-18 | 2026-04-10 | 0.04 |
| 2026-03-13 | 2026-03-17 | 70.47 |
| 2026-02-27 | 2026-03-12 | 0.08 |
| 2026-02-21 | 2026-02-26 | 165.15 |
| 2025-12-11 | 2025-12-15 | 329.99 |
| 2025-10-18 | 2025-11-07 | 5.31 |
| 2025-10-09 | 2025-10-17 | 277.69 |
| 2025-09-16 | 2025-10-08 | 6.54 |
| 2025-09-10 | 2025-09-15 | 323.79 |
| 2025-09-02 | 2025-09-09 | 5.77 |
| 2025-08-13 | 2025-09-01 | 6.37 |
| 2025-08-12 | 2025-08-12 | 362.49 |
| 2025-07-15 | 2025-08-11 | 6.45 |
| 2025-07-09 | 2025-07-14 | 372.07 |
| 2025-06-17 | 2025-07-08 | 6.99 |
| 2025-06-14 | 2025-06-16 | 693.23 |
| 2025-06-11 | 2025-06-13 | 689.89 |
| 2025-05-24 | 2025-06-10 | 2.54 |
| 2025-05-20 | 2025-05-23 | 93.7 |
| 2025-05-17 | 2025-05-19 | 92.42 |
| 2025-04-20 | 2025-05-16 | 2.19 |
| 2025-04-19 | 2025-04-19 | 2.13 |
| 2025-04-14 | 2025-04-18 | 309.63 |
| 2025-04-12 | 2025-04-13 | 308.74 |
| 2025-04-03 | 2025-04-11 | 0.61 |
| 2025-04-02 | 2025-04-02 | 13.95 |
| 2025-03-30 | 2025-04-01 | 43.1 |
| 2025-03-26 | 2025-03-29 | 145.44 |
| 2025-03-23 | 2025-03-25 | 289.35 |
| 2025-03-20 | 2025-03-22 | 317.03 |
| 2025-03-19 | 2025-03-19 | 316.95 |
| 2025-03-15 | 2025-03-18 | 314.74 |
| 2025-02-26 | 2025-03-14 | 1.24 |
| 2025-02-22 | 2025-02-25 | 1.07 |
| 2025-02-21 | 2025-02-21 | 186.07 |
| 2025-02-20 | 2025-02-20 | 222.18 |
| 2025-02-19 | 2025-02-19 | 37.13 |
| 2025-02-12 | 2025-02-18 | 130.0 |
| 2025-01-28 | 2025-02-11 | 0.24 |
| 2025-01-10 | 2025-01-15 | 158.57 |
| 2025-01-03 | 2025-01-09 | 1.55 |
| 2025-01-01 | 2025-01-02 | 415.35 |
| 2024-12-31 | 2024-12-31 | 414.91 |
| 2024-12-29 | 2024-12-30 | 453.92 |
| 2024-12-24 | 2024-12-28 | 452.95 |
| 2024-12-22 | 2024-12-23 | 494.73 |
| 2024-12-20 | 2024-12-21 | 546.68 |
| 2024-12-19 | 2024-12-19 | 546.54 |
| 2024-12-18 | 2024-12-18 | 546.4 |
| 2024-12-17 | 2024-12-17 | 546.26 |
| 2024-12-11 | 2024-12-16 | 543.28 |
| 2024-11-17 | 2024-12-10 | 3.87 |
| 2024-10-16 | 2024-11-16 | 225.65 |
| 2024-09-22 | 2024-10-15 | 0.35 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Testamide, UAB (code 305929638) is a Private Limited Liability Company operating in other hospital activities. In 2025, the company generated revenue of €135.0K and net profit of €16.0K, corresponding to an 11.9% profit margin. Performance improved sharply compared with 2024, when revenue was €52.8K and the company recorded a net loss of €28.8K. Over the two-year period from 2023 to 2025, revenue increased from €60.3K to €135.0K, while losses in 2023 and 2024 turned into a profit in 2025. The latest year also shows stronger operating efficiency, with asset turnover at 1.80x and revenue per employee at €10.4K. At the end of 2025, total assets stood at €74.9K, liabilities at €128.9K, and equity remained negative at €53.9K. Short-term assets accounted for €69.0K, while long-term assets were €5.9K. Profitability and leverage ratios should be interpreted cautiously because equity is negative, which distorts measures such as ROE and debt-based indicators.